Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
Self-learning healthcare systems are becoming a reality. As boundaries between research and healthcare delivery become increasingly blurred, there is an emerging opportunity to accelerate learning through the cyclical integration and analysis of patient phenotype, treatment and clinical outcome. Opportunities already exist to save money through the more efficient use of targeted and immune-based therapies Morgillo et al. [11], Zhao et al. [21], Keenan et al. [5], with a self-learning healthcare system representing an ideal environment for real-world hypothesis testing. Accumulated evidence suggests that interrogation of the genomic events driving cancer can be used to improve patient outcomes. Relatively few studies, however, have integrated complex genomic profiles with deep annotation of patient phenotype, treatment and outcome; where this has been performed, the full potential of genomics to impact the patient pathway has been revealed Gerstung et al. [4]. A single, well-designed genomic assay can deliver >95% of all clinically relevant information for common adult tumour types, including the molecular examples outlined above. Importantly, these data can be delivered in real-world settings, from small amounts of formalin-exposed DNA, in clinically compatible turn-around times at a cost that is affordable to public healthcare systems. Integration of cancer genomic profiling into a self-learning healthcare system represents an opportunity for a step change in how cancer is diagnosed and treated, with beneficial impact on health economics and patient outcomes.